VK2735
VENTURE
Viking Therapeutics · Phase 2 · Completed · Enrollment 176
The paper states the 2.5 mg and 15 mg ends of the weekly range, and the placebo result. It does not state each intermediate dose in the abstract cited here, so those registry arms stay n/r.
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| VK2735 (Placebo) | n/r | n/r | n/r | n/r |
| VK2735 (Dose #1) | n/r | n/r | n/r | n/r |
| VK2735 (Dose #2) | n/r | n/r | n/r | n/r |
| VK2735 (Dose #3) | n/r | n/r | n/r | n/r |
| VK2735 (Dose #4) | n/r | n/r | n/r | n/r |
| VK2735 2.5 mg | n/r | n/r | n/r | n/r |
| VK2735 15 mg | n/r | n/r | n/r | n/r |
| Placebo 13 weeks | n/r | n/r | n/r | n/r |
Not shown
- VK2735 (Placebo): endpoint not reported
- VK2735 (Dose #1): endpoint not reported
- VK2735 (Dose #2): endpoint not reported
- VK2735 (Dose #3): endpoint not reported
- VK2735 (Dose #4): endpoint not reported
- VK2735 2.5 mg: endpoint not reported
- VK2735 15 mg: endpoint not reported
- Placebo 13 weeks: endpoint not reported